Avecho Biotechnology Limited
AVEFF
Other OTC0.00
USD
- -
- -
ISIN
AU0000047441
Return %
Stock
S&P500
1Y
- -
19.01
3Y
28.57
65.48
5Y
-10.00
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Paul Gavin
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2A Westall Road Clayton VIC Australia 3168
- IPO Date
- Aug 24, 2018
- Website
- avecho.com.au
- Similar Companies
- Business
- Avecho Biotechnology Limited (ASX: AVE; OTC: AVEFF), a Melbourne-based biotechnology company founded in 1992 and headquartered in Clayton, Australia, develops, manufactures, sells and licenses innovative human and animal health products utilizing its proprietary Tocopheryl Phosphate Mixture (TPM) drug delivery technology, which enhances drug solubility, stability, bioavailability and transdermal absorption; core offerings include bulk TPM and Vital ET for pharmaceutical, cosmetic and nutraceutical formulations, licensed pain relief gels such as Voveran TPM Gel (Novartis India) and Instanac TPM Gel (Themis Medicare), transdermal patches and injectables for pain and dermatology applications including TPM/Oxymorphone and TPM/Oxycodone, oral and topical pharmaceutical cannabinoid products featuring a Phase III cannabidiol (CBD) TPM soft-gel capsule for insomnia treatment, edible cannabinoid gummies, non-antibiotic livestock feed additives to improve feed efficiency and animal health, and oncology drug formulations replacing toxic solvents with TPM. The company operates through Production, Human Health and other segments, with geographic focus spanning Australia, Switzerland, the Americas, India and additional international markets via licensing and partnerships. Formerly Phosphagenics Limited, it rebranded to Avecho Biotechnology Limited in May 2019; recent developments include a 2025 exclusive 10-year licensing agreement and US$3 million initial payment from Sandoz for commercializing the CBD insomnia capsule in Australia, a strategic alliance with Arthur Group LLC for TPM-enhanced versions of five leading oncology drugs, US patent allowance in 2025 for an optimized TPM manufacturing process, commencement of Phase III insomnia trial dosing with refined 2025 enrollment following 2024 recruitment insights, a major manufacturing campaign for US partner Ashland's Vital ET supply, and two-year stability achievement for the CBD capsule.
Avecho completes treatment phase for Phase III insomnia trial interim analysis